Phase 2 clinical trial will evaluate the safety, translational biology, and exploratory clinical efficacy of VYD2311 in people with Long COVID or ...
Toothio, the leading digital staffing marketplace for dental practices, today launched Mel, the first AI recruiting agent ...
Preliminary Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarterPreliminary ending 2025 cash and cash equival ...
UNIONDALE, NY / ACCESS Newswire / January 22, 2026 / Marquis Who's Who honors Abby Sheneman, PsyD, LCSW, for expertise in ...
This article explores how next-generation vaccines are expanding beyond infectious disease to target chronic conditions while ...
Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 months Notable responses were ...
Sherry Gu, Executive Vice President and CTO at WuXi Biologics, explains the critical challenges of developing bispecific ...
Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 monthsNotable ...
Company expects preliminary unaudited AUCATZYL® net product revenue of approximately $24 million for the fourth quarter of 2025 and approximately ...
The data illustrate that several patients remained on zenocutuzumab well beyond progression, including multiple patients who continued treatment for more than one- or two-years post-progression.
Autolus will evaluate Cellares’ fully automated, high-throughput manufacturing platform in preparation for expansion into new indications ...
CARVYKTI ® is the first and only BCMA-targeted CAR-T cell therapy approved for the treatment of patients with multiple myeloma who have had at least one prior line of therapy. Globally, CARVYKTI ® is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results